LCN9

Across TCGA pan-cancer cohorts, LCN9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LCN9 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LCN9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LCN9 expression acts as an unfavorable survival marker.

BLCA, PAAD, and COAD are the cancer types where LCN9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.159	0.627	<.001	15	view →
PAAD	DFS	Median	All	0.060	0.484	<.001	12	view →
COAD	OS	Median	III,IV	0.054	0.793	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LCN9–BLCA (DFS)

Open the BLCA breakdown →